NCT03941743: Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer

NCT03941743
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with previous exposure to paclitaxel- other chemotherapies are eligible; Current or previous use of fingolimod
https://ClinicalTrials.gov/show/NCT03941743

Comments are closed.

Up ↑